State of The Art Treatment for Hepatitis C
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectable in their blood. Dr. Jorge Herrera joins host Dr. Leslie Lundt to discuss the state of the art for treatment of Hepatitis C.
Overview
Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectable in their blood. Dr. Jorge Herrera joins host Dr. Leslie Lundt to discuss the state of the art for treatment of Hepatitis C.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Updates From the 7th World Symposium Task Force
Chemotherapy Strategies for Metastatic PDAC
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
Partnering with Patients: Building Effective Communication and Support in HF Care
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?